指南与共识免疫规划妇幼与学校卫生

广泛推荐RSV预防后免疫接种接受度:德国横断面研究结果

Immunization acceptance after broad recommendation for RSV prophylaxis: Results from a cross-sectional study in Germany.
指南 / 共识 · Vaccine · 2025-09-11

研究在德国两家大学医院2024-2025年RSV流行季开展横断面调查,519名家长完成问卷,评估对新生儿尼塞韦单抗(nirsevimab)的接受度。结果显示仅40.5%家长同意接种,31.2%犹豫,14.3%拒绝;信息不足、安全担忧和不愿新生儿注射是犹豫主因,作者建议加强针对性教育沟通。

要点

  • 519名家长中仅40.5%同意新生儿使用尼塞韦单抗,31.2%犹豫,14.3%拒绝。
  • 高教育水平、对RSV担忧高及自觉信息充分的家长更可能接受预防。
  • 犹豫主因为信息不足(32.9%)、安全担忧(31.6%)和不愿新生儿注射(22.4%)。

核心结论

  • 德国家长对尼塞韦单抗的接受度低于其他欧洲国家,需加强教育宣传,尤其针对低教育背景家庭。

研究设计与样本

  • 2024-2025年RSV流行季在德国两家大学医院开展的横断面调查,519名家长完成问卷。

主要发现

  • 仅40.5%家长同意尼塞韦单抗接种,31.2%犹豫,14.3%拒绝。
  • 高教育水平、对RSV担忧更高及自觉信息充分的家长接受度显著更高。
  • 犹豫原因包括信息不足(32.9%)、安全担忧(31.6%)和不愿新生儿注射(22.4%)。

关键数值与推荐

  • 原文未报告具体推荐条款或阈值。

临床怎么用

  • 作者建议开展针对性沟通策略,强调安全性和有效性,尤其面向低教育背景家庭,以提高接受度并降低婴儿RSV相关疾病负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study assessed parental acceptance of nirsevimab, a new RSV prophylaxis recommended for newborns in Germany. A cross-sectional survey was conducted at two German university hospitals during the 2024-2025 RSV season, with 519 parents completing questionnaires about their attitudes toward this immunization. Results showed moderate acceptance, with only 40.5 % of parents agreeing to nirsevimab administration, while 31.2 % were undecided and 14.3 % declined. Parents with higher education levels, greater RSV concerns, and those feeling well-informed were significantly more likely to accept the prophylaxis. The primary reasons for hesitancy included insufficient information (32.9 %), safety concerns (31.6 %), and reluctance to give injections to newborns (22.4 %). The study reveals that nirsevimab acceptance among German parents was lower than in other European countries, highlighting the need for enhanced educational campaigns. Targeted communication strategies emphasizing safety and efficacy, particularly for families with lower educational backgrounds, could improve acceptance rates and reduce infant RSV-related morbidity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wetzke M, Lange M, Beinhauer K, et al. Immunization acceptance after broad recommendation for RSV prophylaxis: Results from a cross-sectional study in Germany. Vaccine. 2025. PMID: 40939533. doi:10.1016/j.vaccine.2025.127716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。